Samyang Biopharm Hits Daily Limit After mRNA Cancer Vaccine Delivery Study Gains Attention
Samyang Biopharm hit the daily price limit on Aug. 20 after announcing that preclinical research on NanoReady, its proprietary delivery platform for therapeutic messenger RNA (mRNA) cancer vaccines, had been published in an international scientific journal.The stock was trading at 56,200 won ($40) a
Samyang Biopharm faced the daily price ceiling on August 20 following the announcement of its preclinical research on NanoReady, a proprietary delivery platform for mRNA cancer vaccines. The stock rose 29.79% from the previous session, trading at 56,200 won ($40) as of 9:34 a.m. The surge came after U.S. biotech company Moderna reported positive Phase 3 results for an mRNA-based cancer treatment, reigniting interest in mRNA cancer therapies.
Samyang Biopharm's study, titled "NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity," highlighted the platform's potential for personalized mRNA cancer vaccines. NanoReady, a nanoparticle-based delivery vehicle, selectively targets dendritic cells in the spleen, crucial for immune responses.
Its multilayer structure can carry up to 20 times more mRNA per particle than conventional lipid nanoparticles, potentially enhancing T-cell immune responses against cancer antigens. Repeated dosing was also evaluated, with NanoReady showing no signs of systemic toxicity in nonhuman primate studies, unlike conventional LNPs. Samyang Biopharm plans to further develop its mRNA cancer vaccine pipeline and explore platform-based business opportunities, including global technology licensing and joint drug development.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
